VEGFA and age-related macular degeneration: In this study, six studies (Yu et al., 2021; Dugel et al., 2017; ClinicalTrials.gov, 2013, 2019; Holz et al., 2016; Dugel et al., 2020) were included for meta-analysis to evaluate the efficacy and safety of different anti-VEGF drugs on n-AMD based on BCVA, CSFT, presence of IRF and/or SRF, participants with ≥1 serious adverse events, and participants with ≥1 adverse events (Tamashiro et al., 2022; Zakaria et al., 2022; Montesel et al., 2021).